Clinical trials in adults treated with epigallocatechin-3-gallate, a natural DYRK1a inhibitor from green tea, demonstrated a modest, but detectable gain of cognition in DS individuals (de la Torre et al. 2014, 2016; Xicota et al. 2020). This evidence concerns the gene DYRK1A and Dravet syndrome.